Spanish government starts alliance for health innovation
Madrid - Spain unveiled a grand alliance between all stakeholders in biomedicine to foster innovation in the sector. Minister of Science and Innovation, Cristina Garmendia, met the representatives of institutions, public research centres, companies and employers to sign the charter of Alliance for Research and Innovation in Health (ALINNSA). Garmendia hopes that the alliance will start a process at the end of which there will emerge a national strategy for biomedical research and innovation. An executive committee will work on a common position for Spain to each of the global challenges it faces in this area.
Most of the big names in the Spanish biomedical sector have joined the game. Regina Revilla Pedreira, Chairman of EuropaBio and Humberto Harness Corella, CEO of Farmaindustria are there as well as Jordi Massana Ramentol, the CEO of pharmaceutical giant Ferrer, and José María Fernández Sousa-Faro, President of PharmaMar and the Zeltia Group. The partnership activities will be coordinated by the Instituto de Salud Carlos III (ISCIII), a public research body under the Ministry of Science and Innovation.
The health sector in Spain is in dire straits. US-pharma company Pfizer announced cuts to its workforce in Spain by 11%, or 220 employees, because of the financial crisis in Europe and measures adopted by the Spanish government to slash medical spending.